Results 11 to 20 of about 6,215,751 (161)

Exogenous Flupirtine as Potential Treatment for CLN3 Disease. [PDF]

open access: yesCells, 2020
CLN3 disease is a fatal neurodegenerative disorder affecting children. Hallmarks include brain atrophy, accelerated neuronal apoptosis, and ceramide elevation. Treatment regimens are supportive, highlighting the importance of novel, disease-modifying drugs. Flupirtine and its new allyl carbamate derivative (compound 6) confer neuroprotective effects in
Maalouf K   +8 more
europepmc   +10 more sources

Recognizing differentiating clinical signs of CLN3 disease (Batten disease) at presentation. [PDF]

open access: yesActa Ophthalmol, 2021
AbstractPurposeTo help differentiate CLN3 (Batten) disease, a devastating childhood metabolic disorder, from the similarly presenting early‐onset Stargardt disease (STGD1). Early clinical identification of children with CLN3 disease is essential for adequate referral, counselling and rehabilitation.MethodsMedical chart review of 38 children who were ...
Kuper WFE   +7 more
europepmc   +9 more sources

Gene therapy ameliorates neuromuscular pathology in CLN3 disease. [PDF]

open access: yesActa Neuropathol Commun
CLN3 disease is a neuronopathic lysosomal storage disorder that severely impacts the central nervous system (CNS) while also inducing notable peripheral neuromuscular symptoms. Although considerable attention has been directed towards the neurodegenerative consequences within the CNS, the involvement of peripheral tissues, including skeletal muscles ...
Ziółkowska EA   +14 more
europepmc   +5 more sources

Quantifying lymphocyte vacuolization serves as a measure of CLN3 disease severity. [PDF]

open access: yesJIMD Rep, 2020
AbstractBackgroundThe CLN3 disease spectrum ranges from a childhood‐onset neurodegenerative disorder to a retina‐only disease. Given the lack of metabolic disease severity markers, it may be difficult to provide adequate counseling, particularly when novel genetic variants are identified.
Kuper WFE   +11 more
europepmc   +7 more sources

Cognitive Test Performance in CLN3 Disease Is Associated With the CLN3 Staging System (CLN3SS). [PDF]

open access: yesJIMD Rep
Summary CLN3 disease is an inherited neurodegenerative disease, typically with childhood onset, and characterized by vision loss, seizures, cognitive decline, and difficulties. The CLN3 Staging System (CLN3SS) characterizes disease progression.
Moran SD   +7 more
europepmc   +5 more sources

Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease) [PDF]

open access: yesPLOS ONE, 2016
The neuronal ceroid lipofuscinoses are a group of lysosomal storage disorders that comprise the most common, genetically heterogeneous, fatal neurodegenerative disorders of children. They are characterised by childhood onset, visual failure, epileptic seizures, psychomotor retardation and dementia.
Kim Wager   +5 more
doaj   +10 more sources

Timing of cognitive decline in CLN3 disease. [PDF]

open access: yesJ Inherit Metab Dis, 2018
AbstractBackgroundCLN3 disease is a major cause of childhood neurodegeneration. Onset of visual failure around 6 years of age is thought to precede cognitive deterioration by a few years, but casuistic reports question this paradigm. The aim of our study is to delineate timing of cognitive decline in CLN3 disease.MethodsEarly neurocognitive functioning
Kuper WFE   +5 more
europepmc   +6 more sources

A timeline of symptom onset and disease progression in CLN3 disease. [PDF]

open access: yesOrphanet J Rare Dis
Abstract Background CLN3 disease, or Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), is a rare, genetic neurodegenerative condition, typically manifesting in the first decade of life and progressing in severity, with death typically occurring in early adulthood.
Whiteman IT   +11 more
europepmc   +5 more sources

CLN3 disease disrupts very early postnatal hippocampal maturation. [PDF]

open access: yesSci Rep
CLN3 disease or juvenile neuronal ceroid lipofuscinosis (Batten disease), is a progressive, severe, neurodegenerative, lysosomal storage disorder. Previous studies have demonstrated that network-level excitability differences are present in mouse models prior to significant lysosomal storage accumulation.
Singh JB   +8 more
europepmc   +4 more sources

Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in mice. [PDF]

open access: yesActa Neuropathol Commun
Severe gastrointestinal (GI) symptoms occur in people with CLN3 disease, a neurodegenerative disorder. If left untreated these GI symptoms compromise life quality and may contribute to death.
Ziółkowska EA   +11 more
europepmc   +3 more sources

Home - About - Disclaimer - Privacy